Raquel Farias-Moeller1, Reghann LaFrance-Corey2, Luca Bartolini3, Elizabeth M Wells4, Meredith Baker4, Alyssa Doslea4, William Suslovic4, Jay Greenberg5, Jessica L Carpenter4, Charles L Howe2. 1. Department of Neurology, Division of Pediatric Neurology, Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, Wisconsin. 2. Departments of Neurology and Immunology, Center for MS and Autoimmune Neurology, Translational Neuroimmunology Lab, Mayo Clinic, Rochester, Minnesota. 3. Clinical Epilepsy Section and Division of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke - National Institute of Health, Bethesda, Maryland. 4. Department of Neurology, Children's National Health System, Washington, District of Columbia. 5. Department of Hematology, Children's National Health System, Washington, District of Columbia.
Abstract
OBJECTIVES: Although secondary hemophagocytic lymphohistiocytosis (HLH) has been reported in children with critical illness of various etiologies, it has not been reported in patients with febrile infection-related epilepsy syndrome (FIRES). We describe a series of patients with concurrent HLH and FIRES in an effort to establish common pathophysiologic abnormalities. METHODS: Five patients with FIRES who were assessed for HLH were identified from a neurocritical care database. All were previously healthy and had extensive diagnostic testing. All had clinical deterioration with multiorgan dysfunction prompting HLH screening 20-29 days after hospitalization. Markers for inflammatory dysregulation were assessed in cerebrospinal fluid (CSF) and serum at various time points. Outcomes were assessed 6 months after presentation. RESULTS: Three patients met clinical criteria for secondary HLH. Elevation of specific cytokines/chemokines was variable. CSF neopterin, high mobility group box 1 (HMGB1), and C-X-C motif chemokine ligand 8 (CXCL8) were significantly elevated in all. Interleukin-1β (IL-1β) and IL-18 were not elevated in any of the samples. Treatment and outcomes were variable. SIGNIFICANCE: We describe 3 patients with HLH and FIRES. The co-occurrence of these 2 rare disorders suggests the possibility of a common immune dysregulation phenotype prolonging epileptogenesis. HLH screening in critically ill patients with FIRES may yield a broader understanding of shared inflammatory processes. Wiley Periodicals, Inc.
OBJECTIVES: Although secondary hemophagocytic lymphohistiocytosis (HLH) has been reported in children with critical illness of various etiologies, it has not been reported in patients with febrile infection-related epilepsy syndrome (FIRES). We describe a series of patients with concurrent HLH and FIRES in an effort to establish common pathophysiologic abnormalities. METHODS: Five patients with FIRES who were assessed for HLH were identified from a neurocritical care database. All were previously healthy and had extensive diagnostic testing. All had clinical deterioration with multiorgan dysfunction prompting HLH screening 20-29 days after hospitalization. Markers for inflammatory dysregulation were assessed in cerebrospinal fluid (CSF) and serum at various time points. Outcomes were assessed 6 months after presentation. RESULTS: Three patients met clinical criteria for secondary HLH. Elevation of specific cytokines/chemokines was variable. CSF neopterin, high mobility group box 1 (HMGB1), and C-X-C motif chemokine ligand 8 (CXCL8) were significantly elevated in all. Interleukin-1β (IL-1β) and IL-18 were not elevated in any of the samples. Treatment and outcomes were variable. SIGNIFICANCE: We describe 3 patients with HLH and FIRES. The co-occurrence of these 2 rare disorders suggests the possibility of a common immune dysregulation phenotype prolonging epileptogenesis. HLH screening in critically illpatients with FIRES may yield a broader understanding of shared inflammatory processes. Wiley Periodicals, Inc.
Authors: Yi-Chen Lai; Eyal Muscal; Elizabeth Wells; Nikita Shukla; Krista Eschbach; Ki Hyeong Lee; Marios Kaliakatsos; Nevedita Desai; Ronny Wickström; Maurizio Viri; Elena Freri; Tiziana Granata; Srishti Nangia; Robertino Dilena; Andreas Brunklaus; Mark S Wainwright; Mark P Gorman; Coral M Stredny; Abdurhman Asiri; Khalid Hundallah; Asif Doja; Eric Payne; Elaine Wirrell; Sookyong Koh; Jessica L Carpenter; James Riviello Journal: Ann Clin Transl Neurol Date: 2020-12-04 Impact factor: 5.430
Authors: Michael B Jordan; Carl E Allen; Jay Greenberg; Michael Henry; Michelle L Hermiston; Ashish Kumar; Melissa Hines; Olive Eckstein; Stephan Ladisch; Kim E Nichols; Carlos Rodriguez-Galindo; Birte Wistinghausen; Kenneth L McClain Journal: Pediatr Blood Cancer Date: 2019-07-24 Impact factor: 3.167